Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
CA 2486924 A1 · Owner: Genpat77 Pharmacogenetics Ag · Inventors: Warnke, Peter Christian; Utku, Nalan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and antiangiogenic therapy is described. Provided are agents such as anti-TIRC7 antibodies and methods of treatment which through modulating the activity of TIRC7 can be used for enhancing or suppressing angiogenesis and/or neovascularization, an important feature in many pathological conditions including wound healing, solid tumors, developing metastases ischemic heart , diseases and diabetic retinopathy. Furthermore diagnostic methods for the , detection of such diseases using TIRC7 specific agents are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.